Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS)
CNY 10.0
(2.56%)
CNY 10.0
(2.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 470.72 Million CNY | 262.58% |
| 2022 | 129.82 Million CNY | -52.58% |
| 2021 | 273.75 Million CNY | 127.84% |
| 2020 | 120.15 Million CNY | -19.82% |
| 2019 | 149.85 Million CNY | 208.43% |
| 2018 | -138.2 Million CNY | -85.82% |
| 2017 | -74.37 Million CNY | 75.06% |
| 2016 | -298.22 Million CNY | 41.82% |
| 2015 | -512.59 Million CNY | -3.09% |
| 2014 | -497.21 Million CNY | -292.59% |
| 2013 | -126.65 Million CNY | -154.73% |
| 2012 | -49.71 Million CNY | 38.02% |
| 2011 | -80.21 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 575.92 Million CNY | -16.98% |
| 2024 Q2 | 557.5 Million CNY | -6.37% |
| 2024 Q1 | 595.42 Million CNY | 26.49% |
| 2023 Q3 | 506.75 Million CNY | 20.17% |
| 2023 Q4 | 470.72 Million CNY | -7.11% |
| 2023 Q1 | 274.64 Million CNY | 111.54% |
| 2023 Q2 | 421.68 Million CNY | 53.54% |
| 2023 FY | 470.72 Million CNY | 262.58% |
| 2022 Q4 | 129.82 Million CNY | -47.54% |
| 2022 Q3 | 247.48 Million CNY | -11.79% |
| 2022 Q2 | 280.56 Million CNY | 5.45% |
| 2022 Q1 | 266.05 Million CNY | -2.81% |
| 2022 FY | 129.82 Million CNY | -52.58% |
| 2021 Q4 | 273.75 Million CNY | -35.07% |
| 2021 Q2 | 316.71 Million CNY | 31.14% |
| 2021 Q3 | 421.61 Million CNY | 33.12% |
| 2021 FY | 273.75 Million CNY | 127.84% |
| 2021 Q1 | 241.5 Million CNY | 101.0% |
| 2020 Q1 | 172.57 Million CNY | 15.17% |
| 2020 Q2 | 155.41 Million CNY | -9.95% |
| 2020 Q3 | 191.72 Million CNY | 23.37% |
| 2020 Q4 | 120.15 Million CNY | -37.33% |
| 2020 FY | 120.15 Million CNY | -19.82% |
| 2019 Q3 | 174.02 Million CNY | 51.36% |
| 2019 Q2 | 114.97 Million CNY | 234.36% |
| 2019 Q4 | 149.85 Million CNY | -13.89% |
| 2019 FY | 149.85 Million CNY | 208.43% |
| 2019 Q1 | -85.57 Million CNY | 38.08% |
| 2018 Q1 | -95.57 Million CNY | -28.5% |
| 2018 FY | -138.2 Million CNY | -85.82% |
| 2018 Q4 | -138.2 Million CNY | -187.46% |
| 2018 Q3 | -48.07 Million CNY | 46.76% |
| 2018 Q2 | -90.3 Million CNY | 5.51% |
| 2017 Q4 | -74.37 Million CNY | -26.93% |
| 2017 Q1 | -248.08 Million CNY | 16.81% |
| 2017 Q3 | -58.59 Million CNY | 71.85% |
| 2017 FY | -74.37 Million CNY | 75.06% |
| 2017 Q2 | -208.14 Million CNY | 16.1% |
| 2016 Q1 | -246.39 Million CNY | 53.74% |
| 2016 FY | -298.22 Million CNY | 41.82% |
| 2016 Q3 | -140.21 Million CNY | 47.58% |
| 2016 Q2 | -267.49 Million CNY | -8.56% |
| 2016 Q4 | -298.22 Million CNY | -112.69% |
| 2015 Q2 | -360.83 Million CNY | 1.22% |
| 2015 Q1 | -365.28 Million CNY | 26.53% |
| 2015 Q4 | -532.59 Million CNY | -95.39% |
| 2015 FY | -512.59 Million CNY | -3.09% |
| 2015 Q3 | -272.58 Million CNY | 24.46% |
| 2014 Q2 | -102.39 Million CNY | -180.85% |
| 2014 Q1 | 126.65 Million CNY | 200.0% |
| 2014 Q3 | -108.6 Million CNY | -6.06% |
| 2014 Q4 | -497.21 Million CNY | -357.84% |
| 2014 FY | -497.21 Million CNY | -292.59% |
| 2013 FY | -126.65 Million CNY | -154.73% |
| 2013 Q4 | -126.65 Million CNY | 0.0% |
| 2012 FY | -49.71 Million CNY | 38.02% |
| 2011 FY | -80.21 Million CNY | 0.0% |